Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose of dual immune checkpoint blockade (ICB) before standard chemoradiation is a ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

Investigators evaluated dual immune checkpoint inhibitors for safety and efficacy in patients with brain metastases from rare cancers.

In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of ...

Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors in France. Feasibility of tumor-informed circulating tumor DNA (ctDNA) for molecular ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Distinct molecular features and potential therapeutic strategies for spinal cord gliomas. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...

A research team from the National Center for Nanoscience and Technology of the Chinese Academy of Sciences, in collaboration with Chongqing Medical University, has developed three types of ...